Adrienne M. Dorrance

Adrienne M. Dorrance, PhD

Languages spoken: English

Academic Information

Departments Primary - Internal Medicine

Divisions: Oncology

Academic Office Information

Adrienne.Dorrance@hci.utah.edu

Research Interests

  • Signaling
  • Genetics
  • Hematopoiesis

Education History

Postdoctoral Fellowship Ohio State University Comprehensive Cancer Center - James
 Postdoctoral Research Fellow
Postdoctoral Fellowship Harvard Medical School
 Postdoctoral Research Fellow
Doctoral Training Ohio State University College of Veterinary Medicine
 PhD
Undergraduate Ohio State University
 BSc

Selected Publications

Journal Article

  1. Dorrance AM, Moutuou MM, Goda C, Sell NE, Kalyan S, Karunasiri M, Kulkarni R, Goulard M, Kolovich S, Rudich A, Naumann E, Ackaoui A, Bigras CE, Daudelin F, Garzon R, Ranganathan P, Guimond M (2021). Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice. Blood Adv, 6(7), 2403-2408. (Read full article)
  2. Pepe F, Bill M, Papaioannou D, Karunasiri M, Walker A, Naumann E, Snyder K, Ranganathan P, Dorrance A, Garzon R (2022). Targeting Wnt signaling in acute myeloid leukemia stem cells. Haematologica, 107(1), 307-311. (Read full article)
  3. Snyder KJ, Choe HK, Gao Y, Sell NE, Braunreiter KM, Zitzer NC, Neidemire-Colley L, Kalyan S, Dorrance AM, Keller A, Mihaylova MM, Singh S, Sehgal L, Bollag G, Ma Y, Powell B, Devine SM, Ranganathan P (2021). Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-Versus-Host Disease. Front Oncol, 11, 760789. (Read full article)
  4. Zhang B, Nguyen LXT, Zhao D, Frankhouser DE, Wang H, Hoang DH, Qiao J, Abundis C, Brehove M, Su YL, Feng Y, Stein A, Ghoda L, Dorrance A, Perrotti D, Chen Z, Han A, Pichiorri F, Jin J, Jovanovic-Talisman T, Caligiuri MA, Kuo CJ, Yoshimura A, Li L, Rockne RC, Kortylewski M, Zheng Y, Carlesso N, Kuo YH, Marcucci G (2021). Treatment-induced arteriolar revascularization and miR-126 enhancement in bone marrow niche protect leukemic stem cells in AML. J Hematol Oncol, 14(1), 122. (Read full article)
  5. Di Marcantonio D, Martinez E, Kanefsky JS, Huhn JM, Gabbasov R, Gupta A, Krais JJ, Peri S, Tan Y, Skorski T, Dorrance A, Garzon R, Goldman AR, Tang HY, Johnson N, Sykes SM (2021). ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia. Mol Cell, 81(13), 2752-2764.e6. (Read full article)
  6. Dorrance A (2021). "Mast"ering drug discovery with iPSCs. Blood, 137(15), 1993-1994. (Read full article)
  7. Carpenter RS, Marbourg JM, Brennan FH, Mifflin KA, Hall JCE, Jiang RR, Mo XM, Karunasiri M, Burke MH, Dorrance AM, Popovich PG (2020). Spinal cord injury causes chronic bone marrow failure. Nat Commun, 11(1), 3702. (Read full article)
  8. Bill M, Pathmanathan A, Karunasiri M, Shen C, Burke MH, Ranganathan P, Papaioannou D, Zitzer NC, Snyder K, LaRocco A, Walker AE, Brannan ZJ, Nalin AP, Freud AG, Dikov MM, Zhang X, Bloomfield CD, Garzon R, Dorrance AM (2019). EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia. Clin Cancer Res, 26(3), 669-678. (Read full article)
  9. Papaioannou D, Volinia S, Nicolet D, wierniak M, Petri A, Mrzek K, Bill M, Pepe F, Walker CJ, Walker AE, Carroll AJ, Kohlschmidt J, Eisfeld AK, Powell BL, Uy GL, Kolitz JE, Wang ES, Kauppinen S, Dorrance A, Stone RM, Byrd JC, Bloomfield CD, Garzon R (2019). Clinical and functional significance of circular RNAs in cytogenetically normal AML. Blood Adv, 4(2), 239-251. (Read full article)
  10. Papaioannou D, Petri A, Dovey OM, Terreri S, Wang E, Collins FA, Woodward LA, Walker AE, Nicolet D, Pepe F, Kumchala P, Bill M, Walker CJ, Karunasiri M, Mrzek K, Gardner ML, Camilotto V, Zitzer N, Cooper JL, Cai X, Rong-Mullins X, Kohlschmidt J, Archer KJ, Freitas MA, Zheng Y, Lee RJ, Aifantis I, Vassiliou G, Singh G, Kauppinen S, Bloomfield CD, Dorrance AM, Garzon R (2019). The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia. Nat Commun, 10(1), 5351. (Read full article)
  11. Bill M, Papaioannou D, Karunasiri M, Kohlschmidt J, Pepe F, Walker CJ, Walker AE, Brannan Z, Pathmanathan A, Zhang X, Mrzek K, LaRocco A, Volinia S, Bloomfield CD, Garzon R, Dorrance AM (2019). Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. Leukemia, 33(9), 2169-2182. (Read full article)
  12. Lovat F, Fassan M, Sacchi D, Ranganathan P, Palamarchuk A, Bill M, Karunasiri M, Gasparini P, Nigita G, Distefano R, Veneziano D, Dorrance AM, Garzon R, Croce CM (2018). Knockout of both miR-15/16 loci induces acute myeloid leukemia. Proc Natl Acad Sci U S A, 115(51), 13069-13074. (Read full article)
  13. Mani R, Goswami S, Gopalakrishnan B, Ramaswamy R, Wasmuth R, Tran M, Mo X, Gordon A, Bucci D, Lucas DM, Mims A, Brooks C, Dorrance A, Walker A, Blum W, Byrd JC, Lozanski G, Vasu S, Muthusamy N (2018). The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors. Haematologica, 103(8), 1288-1297. (Read full article)
  14. Zhang B, Nguyen LXT, Li L, Zhao D, Kumar B, Wu H, Lin A, Pellicano F, Hopcroft L, Su YL, Copland M, Holyoake TL, Kuo CJ, Bhatia R, Snyder DS, Ali H, Stein AS, Brewer C, Wang H, McDonald T, Swiderski P, Troadec E, Chen CC, Dorrance A, Pullarkat V, Yuan YC, Perrotti D, Carlesso N, Forman SJ, Kortylewski M, Kuo YH, Marcucci G (2018). Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia. Nat Med, 24(4), 450-462. (Read full article)
  15. He Z, Hu X, Liu W, Dorrance A, Garzon R, Houghton PJ, Shen C (2016). P53 suppresses ribonucleotide reductase via inhibiting mTORC1. Oncotarget, 8(25), 41422-41431. (Read full article)
  16. Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Oakes CC, Steiner DJ, Marcucci G, Powell BL, Kolitz JE, Carter TH, Wang ES, Mrzek K, Croce CM, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance AM (2017). Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci U S A, 114(23), E4641-E4647. (Read full article)
  17. Zhou X, Liu W, Hu X, Dorrance A, Garzon R, Houghton PJ, Shen C (2017). Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Sci Rep, 7(1), 1535. (Read full article)
  18. Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, McNeil B, Bhatnagar B, Shacham S, Kauffman M, Dorrance AM, Blum W, Sampath D, Landesman Y, Garzon R (2016). XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus. Clin Cancer Res, 22(24), 6142-6152. (Read full article)
  19. Leoncini PP, Bertaina A, Papaioannou D, Flotho C, Masetti R, Bresolin S, Menna G, Santoro N, Zecca M, Basso G, Nigita G, Veneziano D, Pagotto S, DOvidio K, Rota R, Dorrance A, Croce CM, Niemeyer C, Locatelli F, Garzon R (2016). MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. Oncotarget, 7(34), 55395-55408. (Read full article)
  20. Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J, Hill EB, Yadav M, Bolon BN, Lee RJ, Lee LJ, Croce CM, Garzon R, Caligiuri MA, Bloomfield CD, Marcucci G (2015). Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia, 29(11), 2143-53. (Read full article)
  21. Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci G (2015). Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia, 29(10), 1981-92. (Read full article)
  22. Ozer HG, Usubalieva A, Dorrance A, Yilmaz AS, Caligiuri M, Marcucci G, Huang K (2015). Identification of medium-sized copy number alterations in whole-genome sequencing. Cancer Inform, 13(Suppl 3), 105-11. (Read full article)
  23. Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrzek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci G (2014). SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. J Clin Invest, 124(4), 1512-24. (Read full article)
  24. Bernot KM, Nemer JS, Santhanam R, Liu S, Zorko NA, Whitman SP, Dickerson KE, Zhang M, Yang X, McConnell KK, Ahmed EH, Muoz MR, Siebenaler RF, Marcucci GG, Mundy-Bosse BL, Brook DL, Garman S, Dorrance AM, Zhang X, Zhang J, Lee RJ, Blum W, Caligiuri MA, Marcucci G (2013). Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease. Blood, 122(23), 3778-83. (Read full article)
  25. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D (2013). PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest, 123(10), 4144-57. (Read full article)
  26. Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrzek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G (2012). Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia, 27(4), 871-8. (Read full article)
  27. Dorrance AM, De Vita S, Radu M, Reddy PN, McGuinness MK, Harris CE, Mathieu R, Lane SW, Kosoff R, Milsom MD, Chernoff J, Williams DA (2013). The Rac GTPase effector p21-activated kinase is essential for hematopoietic stem/progenitor cell migration and engraftment. Blood, 121(13), 2474-82. (Read full article)
  28. Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrzek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G (2012). Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood, 121(1), 159-69. (Read full article)
  29. Zorko NA, Bernot KM, Whitman SP, Siebenaler RF, Ahmed EH, Marcucci GG, Yanes DA, McConnell KK, Mao C, Kalu C, Zhang X, Jarjoura D, Dorrance AM, Heerema NA, Lee BH, Huang G, Marcucci G, Caligiuri MA (2012). Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. Blood, 120(5), 1130-6. (Read full article)
  30. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, Valent P, Hochhaus A, Hughes TP, van der Kuip H, Sattler M, Wiktor-Jedrzejczak W, Richardson C, Dorrance A, Stoklosa T, Williams DA, Skorski T (2012). Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood, 119(18), 4253-63. (Read full article)
  31. Lane SW, De Vita S, Alexander KA, Karaman R, Milsom MD, Dorrance AM, Purdon A, Louis L, Bouxsein ML, Williams DA (2011). Rac signaling in osteoblastic cells is required for normal bone development but is dispensable for hematopoietic development. Blood, 119(3), 736-44. (Read full article)
  32. Sanchez-Aguilera A, Lee YJ, Lo Celso C, Ferraro F, Brumme K, Mondal S, Kim C, Dorrance A, Luo HR, Scadden DT, Williams DA (2011). Guanine nucleotide exchange factor Vav1 regulates perivascular homing and bone marrow retention of hematopoietic stem and progenitor cells. Proc Natl Acad Sci U S A, 108(23), 9607-12. (Read full article)
  33. Guimond M, Freud AG, Mao HC, Yu J, Blaser BW, Leong JW, Vandeusen JB, Dorrance A, Zhang J, Mackall CL, Caligiuri MA (2010). In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis. J Immunol, 184(6), 2769-75. (Read full article)
  34. Dorrance AM, Liu S, Chong A, Pulley B, Nemer D, Guimond M, Yuan W, Chang D, Whitman SP, Marcucci G, Caligiuri MA (2008). The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele. Blood, 112(6), 2508-11. (Read full article)
  35. Dorrance AM, Liu S, Yuan W, Becknell B, Arnoczky KJ, Guimond M, Strout MP, Feng L, Nakamura T, Yu L, Rush LJ, Weinstein M, Leone G, Wu L, Ferketich A, Whitman SP, Marcucci G, Caligiuri MA (2006). Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations. J Clin Invest, 116(10), 2707-16. (Read full article)
  36. Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C, Klisovic MI, Maharry K, Guimond M, Strout MP, Becknell B, Dorrance A, Klisovic RB, Plass C, Bloomfield CD, Marcucci G, Caligiuri MA (2005). The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood, 106(1), 345-52. (Read full article)
  37. Rosenbloom AJ, Linden PK, Dorrance A, Penkosky N, Cohen-Melamed MH, Pinsky MR (2005). Effect of granulocyte-monocyte colony-stimulating factor therapy on leukocyte function and clearance of serious infection in nonneutropenic patients. Chest, 127(6), 2139-50. (Read full article)
  38. Rosenbloom AJ, Pinsky MR, Napolitano C, Nguyen TS, Levann D, Pencosky N, Dorrance A, Ray BK, Whiteside T (1999). Suppression of cytokine-mediated beta2-integrin activation on circulating neutrophils in critically ill patients. J Leukoc Biol, 66(1), 83-9. (Read full article)

Letter

  1. Bill M, Goda C, Pepe F, Ozer HG, McNeil B, Zhang X, Karunasiri M, Kulkarni R, Kalyan S, Papaioannou D, Ferenchak G, Garzon R, Bradner JE, Marcucci G, Caligiuri MA, Dorrance AM (2021). Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the MLL gene. [Letter to the editor]. Haematologica, 106(9), 2527-2532. (Read full article)
  2. Bernot KM, Siebenaler RF, Whitman SP, Zorko NA, Marcucci GG, Santhanam R, Ahmed EH, Ngangana M, McConnell KK, Nemer JS, Brook DL, Kulp SK, Chen CS, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance AM, Dickerson KE, Jarjoura D, Blum W, Marcucci G, Caligiuri MA (2013). Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. [Letter to the editor]. Leukemia, 27(12), 2379-82. (Read full article)

Patent

  1. Dorrance A, Guimond M (2020). Epidermal Growth Factor-Like 7 Peptide and Uses Thereof. U.S. Patent No. T2020-166. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Dorrance A, Garzon R (2017). Recombinant EGFL7, EGFL7 Antibodies, and Uses Thereof. U.S. Patent No. T2017-126. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Garzon R, Dorrance A, Papaionnau D, Lee RJ (2017). Targeting HOXB-AS3 in AML.